Article provision system, article provision processing device, and program

Abstract

To provide an article provision system, an article provision processing device, and a program to prevent health hazards caused by overdose of medicine.SOLUTION: When a user selects to purchase a medicine package containing multiple medicines, an amount of specified components of anti-abuse components in the medicine package selected to be purchased is calculated. An amount of estimated components to estimate the amount of the specified components within a predetermined period of time is calculated based on the calculated amount of the specified components and the medication history information on the anti-abuse components contained in the medicine package provided to the user in the past. When it is determined that the calculated amount of the estimated components to be taken exceeds a pre-defined upper limit of medication, the provision of the medicine package selected by the user to be purchased is discontinued.SELECTED DRAWING: Figure 9

Description

Technical Field

[0001] <Omitted text> The present invention relates to a product providing system, a product providing processing apparatus, and a program for determining the provision of pharmaceuticals. <Omitted text>

Background Art

[0002] <Omitted text> In recent years, there has been a consideration of providing pharmaceuticals from so-called online sales via the Internet, vending machines, etc. <Omitted text> <Omitted text>

[0003] <Omitted text> For example, when providing pharmaceuticals from a vending machine, when using a pre-installed vending machine (drug supply device, sales instrument) to conduct a consultation with a pharmacist via a video conference system or the like, and deciding to purchase the pharmaceuticals recommended by the pharmacist during the consultation, it is known that the pharmaceuticals are provided from the vending machine by the operation and instruction of the pharmacist (see, for example, Patent Document 1 and Patent Document 2). <Omitted text>

Prior Art Documents

Patent Documents

[0004] <Omitted text> <Omitted text>

Patent Document 1

Patent Document 2

Summary of the Invention

Problems to be Solved by the Invention

[0005] <Omitted text> However, in the administration of pharmaceuticals, there is a problem that the person taking the pharmaceuticals may overdose on the pharmaceuticals, resulting in health damage. In particular, the easier it is to purchase pharmaceuticals, the more serious the problem of health damage due to overdose of pharmaceuticals has become. <Omitted text> Therefore, when providing pharmaceuticals, preventing health damage due to overdose of pharmaceuticals is an important issue. <Omitted text> <Omitted text>

[0006] <Omitted text> The present invention is intended to solve the above-mentioned problems, and aims to provide a product provision system, a product provision processing device, and a program that prevent health damage caused by excessive intake of medicines. [Means for solving the problem]

[0007] In order to solve the above-mentioned problems, the product provision system of the present invention is characterized by comprising: a user identification means (such as My Number, app ID, or unique information obtained by facial recognition) for identifying a user; an ingredient amount calculation means for calculating, when a user selects to purchase a pharmaceutical package containing multiple pharmaceuticals, an amount of a specific ingredient (an abuse-preventing ingredient) contained in the pharmaceutical package selected to be purchased; an estimated medication amount calculation means for calculating an estimated medication amount, which estimates the amount of a specific ingredient within a predetermined period, based on the amount of the specific ingredient calculated by the ingredient amount calculation means and medication history information regarding pharmaceutical packages previously provided to the user identified by the user identification means; an abuse prevention determination means for determining whether the estimated medication amount calculated by the estimated medication amount calculation means exceeds a predetermined upper medication limit; and a provision determination means for allowing the provision of the pharmaceutical package selected to be purchased by the user when it is determined by the abuse prevention determination means that the estimated medication amount is equal to or less than the upper medication limit, and for canceling the provision of the pharmaceutical package selected to be purchased by the user when it is determined by the abuse prevention determination means that the estimated medication amount exceeds the upper medication limit.

[0008] Preferably, when the user selects to purchase a plurality of the same drug packages, the component amount calculation means calculates the total component amount of the specific component contained in the plurality of drug packages as the specific component amount; When it is selected by the user to purchase a plurality of identical pharmaceutical packages, and when the abuse prevention determination means determines that the estimated drug component amount exceeds the upper limit value of drug intake, among the plurality of identical pharmaceutical packages, provision of the pharmaceutical packages up to the permitted number for which the estimated drug component amount is equal to or less than the upper limit value of drug intake is permitted, while it is desirable to discontinue provision of the pharmaceutical packages exceeding the permitted number among the plurality of identical pharmaceutical packages.

[0009] Preferably, when it is selected by the user to purchase different pharmaceutical packages, the component amount calculation means extracts the component amounts of the specific components included in each pharmaceutical package, and calculates the specific component amount by summing the extracted component amounts.

[0010] Preferably, it includes a plurality of product providing processing devices that provide pharmaceutical packages, and a server connected to be able to transmit and receive information through a public line with the plurality of product providing processing devices. The server has storage means for storing the medication history information, and medication history information transmission means for transmitting the medication history information stored in the storage means to the product providing processing device when receiving predetermined request information from the product providing processing device. When providing a pharmaceutical package, the product providing processing device preferably has purchase information transmission means for transmitting, in association with each other, the information of the provided pharmaceutical package and the information of the user who provided the pharmaceutical package to the server.

[0011] Preferably, when providing a pharmaceutical package, it further preferably includes medication component amount adjustment means for reducing the estimated drug component amount for each number of days elapsed since the date of provision of the pharmaceutical package.

[0012] Preferably, when it is selected that the user purchases a pharmaceutical package, the estimated dose component amount calculating means calculates the estimated dose component amount by subtracting the amount of the component already taken, which is the daily dose of the specific component multiplied by the number of days elapsed since the first day of the provision date, from the total specific component amount obtained by adding the specific component amount on the current day calculated by the component amount calculating means and the past component amount of the specific component included in the pharmaceutical package provided in the past.

[0013] Preferably, it is desirable to include a specific component extraction means for extracting a specific component included in a pharmaceutical package selected by the user for purchase, a contraindication prevention determination means for determining whether a pharmaceutical package containing a contraindicated component that is contraindicated in combination with the specific component calculated by the specific component extraction means has been provided in the past, and a caution notification means for notifying a caution when the contraindication prevention determination means determines that a pharmaceutical package containing a contraindicated component has been provided in the past.

[0014] Preferably, the product providing processing apparatus of the present invention includes a user identification means for identifying a user, a component amount calculating means for calculating a specific component amount of a specific component included in a pharmaceutical package selected by the user for purchase when it is selected that the user purchases a pharmaceutical package containing a plurality of pharmaceuticals, a dose estimation component amount calculating means for calculating an estimated dose component amount of the specific component within a predetermined period based on the specific component amount calculated by the component amount calculating means and the medication history information regarding the pharmaceutical package provided to the user in the past identified by the user identification means, an abuse prevention determination means for determining whether the estimated dose component amount calculated by the dose estimation component amount calculating means exceeds a predetermined dose upper limit value, and a provision determination means capable of permitting the provision of the pharmaceutical package selected by the user for purchase when the abuse prevention determination means determines that the estimated dose component amount is equal to or less than the dose upper limit value, and stopping the provision of the pharmaceutical package selected by the user for purchase when the abuse prevention determination means determines that the estimated dose component amount exceeds the dose upper limit value.

[0015] Preferably, the program of the present invention is a program for causing a computer to execute: a user identification process for identifying a user; a component amount calculation process for calculating a specific component amount of a specific component included in a pharmaceutical package in which a plurality of pharmaceuticals are included when it is selected to purchase the pharmaceutical package; a medication estimated component amount calculation process for calculating a medication estimated component amount for estimating the component amount of the specific component within a predetermined period based on the specific component amount calculated by the component amount calculation process and the medication history information regarding the pharmaceutical packages previously provided to the user identified by the user identification process; an abuse prevention determination process for determining whether or not the medication estimated component amount calculated by the medication estimated component amount calculation process exceeds a predetermined medication upper limit value; and a provision determination process capable of permitting the provision of the pharmaceutical package selected by the user to be purchased when it is determined by the abuse prevention determination process that the medication estimated component amount is equal to or less than the medication upper limit value, and stopping the provision of the pharmaceutical package selected by the user to be purchased when it is determined by the abuse prevention determination process that the medication estimated component amount exceeds the medication upper limit value.

Effect of the Invention

[0016] According to the present invention, when the medication estimated component amount exceeds the medication upper limit value for the specific component included in the pharmaceutical package desired to be purchased by the user, the provision of the pharmaceutical package is not permitted, so that health damage due to excessive intake of the pharmaceutical can be prevented. In particular, since the component amount of the specific component included in the pharmaceutical package is determined, health damage due to excessive intake of the pharmaceutical can be more firmly prevented for users taking the same specific component without being limited to the same pharmaceutical package or being distinguished between pioneer pharmaceuticals and follow-on pharmaceuticals (generic pharmaceuticals).

Brief Description of the Drawings

[0017]

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Figure 9

Figure 10

Figure 11

Figure 12

Figure 13

Figure 14

Best Mode for Carrying Out the Invention

[0018] Hereinafter, embodiments of the present invention will be described in detail with reference to the drawings. The embodiments described below show some examples of the present invention and do not limit the content of the present invention. Also, not all of the configurations and operations described in each embodiment are essential as the configurations and operations of the present invention.

[0019] In this embodiment, a person who intends to purchase a pharmaceutical product (a person who wishes to purchase) and a person who has purchased a pharmaceutical product (a purchaser) are also appropriately referred to as "users".

[0020] Also, the "pharmaceutical product" provided in this embodiment means a medical pharmaceutical product, a pharmaceutical product requiring guidance, a general pharmaceutical product (Class I pharmaceutical product, Class II pharmaceutical product, or Class III pharmaceutical product), or a quasi-drug. The "pharmaceutical package" contains a plurality of pharmaceutical products and is packaged when providing the pharmaceutical products, corresponding to a packaged box, bottle, or medicine bag prescribed by a pharmacist sold at a pharmacy or a drugstore.

[0021] Also, in this embodiment, the direction facing the user when the user operates the merchandise providing processing apparatus is referred to as "front", and the direction opposite to the front is referred to as "rear". Also, in this embodiment, the vertical direction and height direction of the merchandise providing processing apparatus are referred to as the "vertical direction", and the horizontal direction and width direction of the merchandise providing processing apparatus are referred to as the "lateral direction".

[0022] [Embodiment 1] The merchandise providing system 1 and the merchandise providing processing apparatus 100 according to Embodiment 1 of the present invention will be described. The merchandise providing processing apparatus 100 according to Embodiment 1 is a vending machine capable of providing a pharmaceutical package. This merchandise providing processing apparatus 100 is installed inside a store of a retailer such as a pharmacy, a drugstore, or a convenience store.

[0023] [External Configuration of Merchandise Providing Processing Apparatus] First, the external configuration of the product providing processing apparatus 100 according to Embodiment 1 will be described. FIG. 1 is an example of a perspective view of the product providing processing apparatus 100 according to Embodiment 1.

[0024] As shown in FIG. 1, a door 3 is provided on the front surface of the housing 2 of the product providing processing apparatus 100. In the product providing processing apparatus 100, when the door 3 is opened, a replenisher performs operations such as replenishment of pharmaceuticals and collection of payment for pharmaceuticals.

[0025] On the front side of the door 3, a touch screen including a display unit 10 for displaying explanations of pharmaceuticals, code information such as QR codes (registered trademarks), etc., and an operation input unit 11 for receiving a user's selection operation is provided.

[0026] In addition, on the front surface of the door 3, a product outlet 12 for the user to take out the purchased pharmaceuticals is provided. In front of and on the upper end side of this product outlet 12, a transparent opening / closing door 13 for preventing the intrusion of dust, sand, and pests is pivotally supported.

[0027] In the present embodiment, the product outlet 12 is provided at a slightly central portion of the door 3. Therefore, the user can take out the purchased pharmaceuticals in a stable posture without bending the back or knees. Note that the product outlet 12 may be provided in the lower portion of the door 3 or in the upper portion of the door 3.

[0028] In addition, on the upper portion of the front side of the door 3, a speaker 19 for outputting sound or the like and an external camera 20 for photographing the user are provided.

[0029] And on the front surface of the door 3 of the product providing processing apparatus 100, a coin insertion unit 14 for receiving coins, a bill validator unit 15 for receiving bills, a code reader 16 capable of reading QR codes, and an IC card reader 17 capable of reading a My Number card are provided. Further, a change outlet 18 for taking out change is provided.

[0030] In addition, the merchandise providing processing device 100 may include an electronic money settlement terminal (for example, an NFC settlement terminal) capable of depositing electronic money through short-range wireless communication that is contactless with a card settlement unit or a user terminal device 300.

[0031] Inside the merchandise providing processing device 100, pharmaceutical packages are stored separately for each type of pharmaceutical package. And when permission is given to provide a pharmaceutical package, a driving device 50 (see FIG. 2) such as a motor is driven, and the pharmaceutical package is conveyed to the merchandise outlet 12.

[0032] In addition, the merchandise providing processing device 100 may be provided with a receipt printer that outputs a receipt and may be configured so that the purchase history of the pharmaceutical package can be confirmed.

[0033] Furthermore, the merchandise providing processing device 100 may be provided with a refrigerator and configured so that the temperature inside the merchandise providing processing device 100 can be appropriately adjusted, or may be provided with a dehumidifier and configured so that the humidity inside the merchandise providing processing device 100 can be appropriately adjusted.

[0034] [Configuration of the Merchandise Providing System] Next, the configuration of a merchandise providing system in which pharmaceuticals are provided via the merchandise providing processing device 100 will be described. FIG. 2 is an example of a block diagram showing the configuration of the merchandise providing system 1 according to Embodiment 1.

[0035] As shown in FIG. 2, the merchandise providing system 1 according to Embodiment 1 includes a plurality of merchandise providing processing devices 100 installed in different locations, a server 200 that performs various processes, and a user terminal device 300.

[0036] The merchandise providing processing device 100 includes at least a display unit 10, an operation input unit 11, a code reader 16, an IC card reader 17, a speaker 19, an external camera 20, a control unit 30, a device program storage unit 40, a control storage unit 41, a driving device 50, a money information input / output unit 60, and a communication unit 70.

[0037] The control unit 30 consists of a processor such as a CPU (Central Processing Unit), and is connected to various devices (display unit 10, operation input unit 11, code reader 16, IC card reader 17, speaker 19, external camera 20, device program storage unit 40, control storage unit 41, drive device 50, money information input / output unit 60, communication unit 70). The control unit 30 executes the programs stored in the device program storage unit 40 to perform various processes for providing pharmaceuticals. Details of the processes of the control unit 30 will be described later.

[0038] The device program storage unit 40 consists of a non-rewritable non-volatile ROM such as a mask ROM, and stores programs for causing the control unit 30 to perform various processes.

[0039] The control storage unit 41 is a temporary storage device, and consists of, for example, a readable and writable non-volatile flash memory or the like, and stores temporary information for the control unit 30 to perform various processes.

[0040] The drive device 50 consists of a belt conveyor, elevator, pusher, motor, etc., and is a device for transporting pharmaceuticals to the product outlet 12.

[0041] The money information input / output unit 60 is connected to the coin insertion unit 14, the bill validator unit 15, and the change outlet 18, and is a payment unit for inputting and outputting money information, card information, and change information.

[0042] The communication unit 70 consists of a communication module that establishes a communication state between the product providing processing device 100 and the server 200 to enable mutual communication, and the communication method may be wired communication or wireless communication.

[0043] The server 200 is composed of a server control unit 210, a database storage unit 220, and a server program storage unit 230.

[0044] The server control unit 210 consists of a processor such as a CPU and is connected to the database storage unit 220 and the server program storage unit 230. The server control unit 210 executes the program stored in the server program storage unit 230 to update the medication history information stored in the database storage unit 220, or transmit the medication history information to the product offering processing device 100, and perform various processes.

[0045] The database storage unit 220 consists of a large-capacity storage device such as a hard disk drive (HDD), a solid state drive (SDD), an optical disk drive, or a magnetic tape device, and stores pharmaceutical package component information, medication history information, combination contraindication information, reservation purchase information, etc.

[0046] The "pharmaceutical package component information" defines the upper limit of medication within one time or during a continuous medication period estimated from the estimated dangerous amount for each abuse prevention component that may cause health damage due to excessive intake of pharmaceuticals, and is information that is database-ized in units of pharmaceutical packages. The detailed configuration of the pharmaceutical package component information will be described later with reference to Fig. 3(a).

[0047] The "medication history information" is composed of information on specific components included in pharmaceutical packages purchased by the user in the past, associated with the user's unique information. The detailed configuration of the medication history information will be described later with reference to Fig. 3(b).

[0048] The "combination contraindication information" is composed of information on contraindication combinations of various component information that are contraindicated for combination, and caution combinations of various component information that require caution for combination.

[0049] The "reservation purchase information" is composed of information on pharmaceutical packages reserved for purchase, associated with the user's unique information.

[0050] The user terminal device 300 consists of terminal devices such as a personal computer, a tablet, and a smartphone, and is a terminal device operated by the user. The user can make a purchase reservation for a pharmaceutical package in advance by operating the user terminal device 300 and receive the reserved pharmaceutical product from the product providing device 100.

[0051] Note that the product providing system 1 of the present embodiment is configured to include the user terminal device 300, but it may also be configured without the user terminal device 300.

[0052] Furthermore, the product providing system 1 may be configured to include a pharmacist terminal device for the pharmacist to perform operations and consultations, and enable the user to conduct consultations with the pharmacist via a video conferencing system or the like through the display unit of the product providing device 100 or the user terminal device 300.

[0053] [Configuration of Pharmaceutical Package Component Information] The configuration of the pharmaceutical package component information stored in the database storage unit 220 of the server 200 described above will be explained. FIG. 3(a) is an example of a conceptual diagram showing the configuration of the pharmaceutical package component information according to Embodiment 1.

[0054] As shown in FIG. 3(a), for the "abuse prevention component", the "estimated dangerous amount" and the "upper limit value of medication" are defined in association with each other.

[0055] The "abuse prevention component" indicates a component of a target for which there is a risk of health damage due to excessive intake of the pharmaceutical product, and includes ephedrine, codeine, dihydrocodeine, bromovalerylurea, pseudoephedrine, methylephedrine designated by the Ministry of Health, Labour and Welfare as "pharmaceuticals with a risk of abuse, etc.", acetylsalicylic acid (aspirin), caffeine for which the Ministry of Health, Labour and Welfare has issued a warning, and components for which various medical institutions have issued a warning.

[0056] The "presumed dangerous amount" indicates the amount of a component that may cause health damage for each abuse prevention component, and corresponds to the poisoning amount or presumed lethal amount disclosed by the Ministry of Health, Labour and Welfare or a prescribed medical institution, etc.

[0057] The "upper limit of drug intake" is the upper limit of the amount of a component that prevents health damage caused by an abuse prevention component within one dose or during a continuous drug intake period, and is set by estimating from the presumed dangerous amount for each abuse prevention component.

[0058] As an example of setting the upper limit of drug intake, an upper limit value obtained by multiplying the presumed dangerous amount by a safety factor of 100% is set. When the presumed dangerous amount depends on the weight of the purchaser, a safety consideration is made, and an upper limit value (for example, 30 kg) assuming a lightweight purchaser with no physical strength is set. In addition, when the presumed dangerous amount depends on the weight of the purchaser, the purchaser may be configured to input their weight or have their weight measured, and the upper limit of drug intake may be set based on the actual weight of the purchaser.

[0059] In this embodiment, the pharmaceutical package component information defines the abuse prevention component, the presumed dangerous amount, and the upper limit of drug intake in association with each other. However, the presumed dangerous amount may not be defined, and the abuse prevention component and the upper limit of drug intake may be defined in association with each other.

[0060] Furthermore, the pharmaceutical package component information defines the "pharmaceutical package" in association with the "abuse prevention component", and the "content per one tablet / packet / book", "number of tablets / packets / books per one package", "content per one package (specific component amount)", "number of tablets / packets / books taken per day", "daily drug intake amount", and "ineligible age for drug intake" are defined in association with the "pharmaceutical package".

[0061] The "content per one tablet / packet / book" is the amount of the abuse prevention component contained in one tablet, one packet, or one book of the pharmaceutical package.

[0062] The "number of tablets / packets / books per one package" is the number of tablets, packets, or books contained in one pharmaceutical package.

[0063] "Content per package (specific ingredient amount)" refers to the amount of the abuse prevention ingredient contained in one pharmaceutical package, and is calculated by multiplying the "content per tablet or packet or stick" by the "number of packages (tablets or packets or sticks)".

[0064] "Number of tablets or packets or sticks taken per day" refers to the number of tablets, packets or sticks contained in a pharmaceutical package taken per day.

[0065] "Daily dosage" refers to the amount of the abuse prevention ingredient per day when the number of tablets, packets or sticks contained in a pharmaceutical package is taken per day, and is calculated by multiplying the "content per tablet or packet or stick" by the "number of tablets or packets or sticks taken per day".

[0066] "Age at which taking medicine is not allowed" indicates the age at which the medicine contained in a pharmaceutical package cannot be taken.

[0067] In addition, the pharmaceutical package component information may store other information in association with the "pharmaceutical package", or may not store information such as the age at which taking medicine is not allowed in association.

[0068] [Composition of Medication History Information] The composition of the medication history information stored in the database storage unit 220 of the server 200 described above will be described. FIG. 3(b) is an example of a conceptual diagram showing the composition of the medication history information according to Embodiment 1.

[0069] As shown in FIG. 3(b), the medication history information is defined by associating "user's unique information" with "abuse prevention ingredient", "pharmaceutical package", "content per package (specific ingredient amount)", "number of provided items", "first provided date", "daily dosage", "number of elapsed days", "estimated remaining ingredient amount", and "total estimated remaining ingredient amount".

[0070] The "user's unique information" is information that identifies the user (purchaser), and corresponds to unique information obtained by face authentication photographed by the external camera 20 of the product providing processing device 100, unique information obtained from the driver's license photographed by the external camera 20, information on the user's My Number card, the app ID which is the unique information of the application corresponding to the product providing system 1, etc.

[0071] The "number of provided items" indicates the number of each pharmaceutical package that the product providing processing device 100 has provided to the user in the past.

[0072] The "first provided date" indicates the date when the product providing processing device 100 first provided a pharmaceutical package to the user.

[0073] The "number of elapsed days" indicates the number of days elapsed since the date when each pharmaceutical package was first purchased, and is calculated based on the "first provided date" and the current date.

[0074] The "estimated remaining component amount" indicates the component amount of the abuse prevention component remaining in each pharmaceutical package, and is calculated by subtracting the second multiplication value obtained by multiplying the "daily dosage" by the "number of elapsed days" from the first multiplication value obtained by multiplying the "content per package (specific component amount)" by the "number of provided items".

[0075] The "total estimated remaining component amount" indicates the component amount remaining for each abuse prevention component, and is calculated by summing the "estimated remaining component amount" for each abuse prevention component.

[0076] Also, when the estimated remaining component amount = 0, the information defined in association with the pharmaceutical package is deleted from the medication history information. As a result, the information on the pharmaceutical package that has passed the continuous medication period is deleted, and the medication history information associated with the user's unique information can be appropriately updated.

[0077] In addition, the medication history information may be stored by associating other information with the user's unique information. For example, information such as "gender", "age", or "weight" may be defined in association with the user's unique information.

[0078] [Sequence Diagram of Product Offering System] Next, the process transition of the product offering system 1 will be described. FIG. 4 is an example of a sequence diagram showing the process transition when purchasing a reservation for a pharmaceutical package from a user terminal device in the product offering system according to Embodiment 1. FIG. 5 is an example of a sequence diagram showing the process transition when purchasing a pharmaceutical package from a product offering processing device in the product offering system according to Embodiment 1.

[0079] The sequence diagram shown in FIG. 4 shows the processes of the user terminal device 300, the product offering processing device 100, and the server 200 (server control unit 210) in order from the left column. Note that for each process described below, the elements of step S are illustrated in an exemplary order and are not limited to the specific order shown. Therefore, in the flowchart shown in FIG. 4, the order can be changed as long as there is no contradiction in the processing results. The same applies to FIGS. 5 to 10 described later.

[0080] [Sequence When Reserving the Purchase of a Pharmaceutical Package from the User Terminal Device] The sequence when the user reserves the purchase of a pharmaceutical package using the user terminal device 300 and receives the pharmaceutical package from the product offering processing device 100 will be described.

[0081] As shown in FIG. 4, when there is a login operation from the user to the server control unit 210, the user terminal device 300 performs product selection login processing (step S1). In this product selection login process, first, the user's unique information such as the app ID and password is transmitted to the server 200.

[0082] When the server control unit 210 receives the user's unique information from the user terminal device 300, it performs user authentication processing (step S2). In this user authentication processing, it is determined whether the user's unique information received from the user terminal device 300 is the user's unique information registered in the database storage unit 220. Then, the user authentication result information indicating whether it is the registered user's unique information is transmitted to the user terminal device 300. Also, if the received user's unique information is the previously registered user's unique information, it is regarded that the user's authentication has succeeded, and the received user's unique information is registered as the user's unique information of the user accessing, and the communication state between the server control unit 210 and the user terminal device 300 is established.

[0083] When the user terminal device 300 receives the user authentication result information indicating that the user's authentication has succeeded, it performs a reserved item determination process of reserving the purchase of the pharmaceutical package provided by the product providing device 100 (step S3). In this reserved item determination process, the pharmaceutical package is selected from the pharmaceutical package name or from the symptoms, and the purchase of the pharmaceutical package provided by the product providing device 100 is reserved. Then, the information of the reserved pharmaceutical package is transmitted to the server 200.

[0084] Note that when a pharmaceutical package is reserved for purchase by the reserved item determination process, if the reserved pharmaceutical package contains a specific pharmaceutical product (for example, a Class I pharmaceutical product), it may be configured to cause a pharmacist to conduct a consultation regarding the specific pharmaceutical product by means of a video conference system or the like.

[0085] When the server control unit 210 receives the information of the reserved pharmaceutical package, it performs server health hazard suppression processing (step S4). In this server health hazard suppression process, it is determined whether the reserved pharmaceutical package contains an abuse prevention ingredient. If the reserved pharmaceutical package contains an abuse prevention ingredient, a dosage estimation ingredient amount for estimating the ingredient amount of the abuse prevention ingredient within a predetermined period is calculated, and an abuse prevention determination process is performed to determine whether the calculated dosage estimation ingredient amount exceeds the dosage upper limit value. Further, a contraindication prevention determination process is performed to determine whether the ingredient information included in the reserved pharmaceutical package and the ingredient information included in the pharmaceutical packages provided in the past form a contraindicated combination or a cautionary combination. Details of this server health hazard suppression process will be described later with reference to FIG. 10.

[0086] When the provision of the reserved pharmaceutical package is permitted by the server health hazard suppression process, permission information for permitting the provision of the reserved pharmaceutical package, the pharmaceutical information of the reserved pharmaceutical package, the number of units of the reserved pharmaceutical package to be provided, and code information for issuing a QR code are transmitted to the user terminal device 300. On the other hand, when the provision of the reserved pharmaceutical package is not permitted, non-permission information for not permitting the provision of the reserved pharmaceutical package and the pharmaceutical information of the reserved pharmaceutical package are transmitted to the user terminal device 300.

[0087] The user terminal device 300 determines whether it has received permission information for provision (step S7). When it receives non-permission information for provision, the user terminal device 300 displays a purchase non-permission image indicating that the product cannot be sold because there is a risk of health hazards occurring in the user terminal device 300, and ends the process of reserving the purchase of the pharmaceutical package.

[0088] When the user terminal device 300 receives permission information for provision, it performs a code information storage process of storing the received code information so that a QR code can be issued (step S8).

[0089] The user terminal device 300 performs a code information issuance process for issuing a QR code by a predetermined operation (step S9).

[0090] When the product providing processing device 100 reads the QR code issued to the user terminal device 300, it performs a code information analysis process for analyzing the QR code (step S10). In this code information analysis process, the QR code is analyzed to extract the user's unique information, the reserved pharmaceutical package, and the provided quantity.

[0091] The product providing processing device 100 performs a provided product determination process for determining the pharmaceutical package to be provided (step S11). In this provided product determination process, the pharmaceutical package and the provided quantity extracted by the above code information analysis process are determined.

[0092] When the product providing processing device 100 determines the pharmaceutical package, it performs a purchase payment confirmation process (step S12). In this purchase payment confirmation process, the purchase price is calculated based on the determined pharmaceutical package and the provided quantity, the payment from the user is confirmed from the money information input / output unit 60, and it is determined whether the payment from the user is sufficient for the purchase price.

[0093] When the payment from the user is sufficient for the purchase price, the product providing processing device 100 performs a product providing process for providing the determined pharmaceutical package (step S13). In this product providing process, the driving device 50 is driven to convey the determined number of pharmaceutical packages to the product outlet 12.

[0094] When the product providing processing device 100 provides the determined pharmaceutical package, it performs a purchase information transmission process (step S14). In this purchase information transmission process, the information of the pharmaceutical package provided in association with the user's unique information is transmitted to the server 200.

[0095] When the server control unit 210 receives the information of the provided pharmaceutical package, it performs a medication history information update process for updating the medication history information (step S15). In this medication history information update process, the information of the pharmaceutical package provided in association with the user's unique information is stored and updated in the medication history information.

[0096] Note that in this embodiment, the user terminal device 300 issues a QR code, and the product providing processing device 100 reads the QR code to provide the reserved pharmaceutical package. However, it may be configured such that the product providing processing device 100 issues a QR code, the user terminal device 300 reads the QR code to access the server 200, and the product providing processing device 100 provides the reserved pharmaceutical package according to the instruction from the server 200.

[0097] (Sequence when determining and purchasing a pharmaceutical package from the product providing processing device) The sequence when the user determines and purchases a pharmaceutical package by the product providing processing device will be described. The sequence diagram shown in FIG. 5 shows the processing of the product providing processing device 100 and the server 200 (server control unit 210) in order from the left column.

[0098] As shown in FIG. 5, the product providing processing device 100 performs a reception standby process for receiving an operation from the user or the like (step S21). In this reception standby process, the operation type from the user or the like is discriminated, and the process proceeds to the process corresponding to the operation type.

[0099] When there is a purchase operation of a pharmaceutical package from the user, the product providing processing device 100 performs a user unique information acquisition process for acquiring the user's unique information (step S22). In this user-specific information acquisition process, the user inputs the information of the My Number Card (or reads the My Number Card), inputs the app ID corresponding to the product offering system 1 (or reads the QR code of the app corresponding to the product offering system 1), and the user's specific information is acquired. Also, when the information of the My Number Card or the app ID is not input, the external camera 20 is activated, and the specific information is acquired by face authentication captured by the external camera 20 or the specific information is acquired from the driver's license. Note that in this embodiment, it is configured to be able to acquire any of the specific information of the information of the My Number Card, the app ID, the specific information by face authentication, and the specific information by driver's license, but it may be configured to be able to acquire only one of the specific information.

[0100] When there is a purchase operation of a pharmaceutical package from the user, the product offering processing device 100 performs a product selection process of selecting the pharmaceutical package provided from the product offering processing device 100 (step S23). In this product selection process, the pharmaceutical package is selected from the pharmaceutical package name or the pharmaceutical package is selected from the symptoms to select the pharmaceutical package that the user wishes to purchase.

[0101] When there is a determination operation of the pharmaceutical package from the user, the product offering processing device 100 performs a product determination process of determining the pharmaceutical package provided from the product offering processing device 100 (step S24).

[0102] When the pharmaceutical package is determined, the product offering processing device 100 performs a user-specific information transmission process to acquire the medication history information associated with the user's specific information from the server 200 (step S25). In this user-specific information transmission process, the history information request information associated with the user's specific information is transmitted to the server 200.

[0103] When the server control unit 210 receives the history information request information, it performs a medication history information transmission process (step S26). In this medication history information transmission process, medication history information corresponding to the user's unique information is extracted, and the extracted medication history information is transmitted to the product offering processing device 100.

[0104] When the product offering processing device 100 receives the medication history information, it performs a medication history information acquisition process for acquiring the medication history information (step S27). In this medication history information acquisition process, the medication history information received from the server 200 is stored in the control storage unit 41.

[0105] When the product offering processing device 100 stores the medication history information, it performs a health hazard suppression process (step S28). In this health hazard suppression process, it is determined whether the pharmaceutical package desired to be purchased contains an abuse prevention ingredient. If the pharmaceutical package desired to be purchased contains an abuse prevention ingredient, a medication estimated ingredient amount calculation for estimating the ingredient amount of the abuse prevention ingredient within a predetermined period is performed, and an abuse prevention determination process for determining whether the calculated medication estimated ingredient amount exceeds the medication upper limit value is performed. Further, a contraindication prevention determination process for determining whether the ingredient information included in the pharmaceutical package desired to be purchased and the ingredient information included in the pharmaceutical packages provided in the past form a contraindicated combination or a cautionary combination is performed. Details of this health hazard suppression process will be described later with reference to FIG. 7.

[0106] The product offering processing device 100 determines whether to permit the provision of the pharmaceutical package desired to be purchased (step S29). If the product offering processing device 100 determines that the provision of the pharmaceutical package desired to be purchased is not permitted, it discards the information of the pharmaceutical package desired to be purchased and the user's unique information, displays a purchase non - permission image indicating that it cannot be sold because there is a risk of health hazards, and ends the process of purchasing the pharmaceutical package.

[0107] When the product offering processing device 100 determines that the provision of the pharmaceutical package desired to be purchased is permitted, it performs a provided product determination process for determining the pharmaceutical package to be provided (step S30). In this provided product determination process, the pharmaceutical package desired to be purchased and the number of provided items are determined.

[0108] When the product providing apparatus 100 determines the pharmaceutical package, it performs a purchase price payment confirmation process (step S31). In this purchase price payment confirmation process, the purchase price is calculated based on the determined pharmaceutical package and the number of provided items, the payment from the user is confirmed from the money information input / output unit 60, and it is determined whether the payment from the user is sufficient for the purchase price.

[0109] When the payment from the user is sufficient for the purchase price, the product providing apparatus 100 performs a product providing process for providing the determined pharmaceutical package (step S32). In this product providing process, the driving device 50 is driven to convey the determined number of pharmaceutical packages to the product outlet 12.

[0110] When the product providing apparatus 100 provides the determined pharmaceutical package, it performs a purchase information transmission process (step S33). In this purchase information transmission process, the information of the pharmaceutical package provided in association with the user's unique information is transmitted to the server 200.

[0111] When the server control unit 210 receives the information of the provided pharmaceutical package, it performs a medication history information update process for updating the medication history information (step S34). In this medication history information update process, the information of the pharmaceutical package provided in association with the user's unique information is stored in the medication history information and updated.

[0112] Note that in this embodiment, the product providing apparatus 100 is configured to acquire the medication history information corresponding to the user's unique information from the server 20 after acquiring the user's unique information, but the product providing apparatus 100 may be configured to periodically acquire the medication history information corresponding to the unique information of all users from the server 200.

[0113] Furthermore, in this embodiment, the product offering processing apparatus 100 is configured to perform the health damage suppression process. However, even when determining and purchasing a pharmaceutical package from the product offering processing apparatus, or when the server 200 is configured to perform the health damage suppression process. In such a configuration, the product offering processing apparatus 100 transmits information on the pharmaceutical package desired to be purchased in association with the user's unique information to the server 200. Similar to the server health damage suppression process (step S4), an abuse prevention determination process and a contraindication prevention determination process are performed on the information on the pharmaceutical package desired to be purchased, and the information on the determination result may be transmitted to the product offering processing apparatus 100.

[0114] As described above, in the product offering system 1 of this embodiment, the medication history information is managed by the server 200, and is configured to be transmitted from the server 200 to each product offering processing apparatus 100. For this reason, the medication history information is shared by all the product offering processing apparatuses 100. Even when purchasing a pharmaceutical package from product offering processing apparatuses 100 installed in different locations, the estimated medication component amounts of the pharmaceutical packages provided by the respective product offering processing apparatuses 100 are totaled. When the totaled estimated medication component amount exceeds the medication upper limit value, the provision of the pharmaceutical package can be stopped. Thereby, it is possible to prevent an attempt to purchase a large amount of pharmaceutical packages at different locations due to drug overdose addiction, and to prevent health damage caused by drug overdose.

[0115] Also, the processing of the user terminal device 300, the product offering processing apparatus 100, and the server 200 (server control unit 210) in the above-described sequence diagram is an example of representative processing, and in addition to this, processing for performing a number of other functions is being performed.

[0116] [Control Processing of Product Offering Processing Apparatus] Next, the details of the control processing of the product offering processing apparatus 100 will be described. FIG. 6 is an example of a flowchart showing the main control processing of the product offering processing apparatus 100 according to Embodiment 1.

[0117] (Main control process of the product providing device) The main control process of the product providing device 100 shown in FIG. 6 is a process performed when power is supplied to the product providing device 100.

[0118] As shown in FIG. 6, in step S101, the control unit 30 performs a power failure recovery process. In this power failure recovery process, various types of information are initialized, communication is confirmed with the server 200, and necessary information is acquired from the server 200. Specifically, pharmaceutical package component information, combination contraindication information, etc. are acquired from the server 200. When this process is completed, the process proceeds to step S102.

[0119] In step S102, the control unit 30 performs a reception standby process for receiving an operation from the user. This reception standby process corresponds to the reception standby process (step S21) shown in FIG. 5, and is a process of displaying a reception display screen for receiving an operation from the user on the display unit 10 and waiting to receive an operation from the user. When an operation from the user is received, the process proceeds to step S103.

[0120] In step S103, the control unit 30 determines whether it has received a receipt operation for the pharmaceutical package reserved for purchase by the user. If the control unit 30 determines that it has received a receipt operation for the reserved pharmaceutical package, the process proceeds to step S104. If it determines that it has not received a receipt operation for the reserved product from the user, the process proceeds to step S110.

[0121] In step S104, the control unit 30 performs a code information reading process for reading the QR code issued to the user terminal device 300. When the QR code issued to the user terminal device 300 is read, the process proceeds to step S105.

[0122] In step S105, the control unit 30 performs a code information analysis process for analyzing the QR code. This code information analysis process corresponds to the code information analysis process (step S10) shown in FIG. 4, analyzes the QR code, and extracts the user's unique information, the reserved pharmaceutical package, and the number of provided items. When this process ends, the process proceeds to step S106.

[0123] In step S106, the control unit 30 performs a provided product determination process for determining the pharmaceutical package to be provided. This provided product determination process corresponds to the provided product determination process (step S11) shown in FIG. 4, and determines the pharmaceutical package and the number of provided items extracted by the above code information analysis process. When this process ends, the process proceeds to step S121.

[0124] In step S110, the control unit 30 determines whether it has received a purchase operation of a product from the user. If the control unit 30 determines that it has received a purchase operation of a product from the user, the process proceeds to step S111. If it determines that it has not received a purchase operation of a product from the user, the process returns to step S102.

[0125] In step S111, the control unit 30 performs a user unique information acquisition process for acquiring the user's unique information. This user-specific information acquisition process corresponds to the user-specific information acquisition process (step S22) shown in FIG. 5. The process acquires the user's specific information when the user inputs the information of the My Number Card (or reads the My Number Card), inputs the app ID corresponding to the product offering system 1 (or reads the QR code of the app corresponding to the product offering system 1). When the information of the My Number Card or the app ID is not input, the external camera 20 is activated, and the specific information is acquired by face authentication captured by the external camera 20 or the specific information is acquired from the driver's license. In the present embodiment, although it is configured to be able to acquire any of the specific information of the My Number Card information, app ID, specific information by face authentication, and specific information by driver's license, it may be configured to be able to acquire only one of the specific information. When this process ends, the process proceeds to step S112.

[0126] In step S112, the control unit 30 performs a product selection process of selecting a pharmaceutical package provided from the product offering device 100. This product selection process corresponds to the product selection process (step S23) shown in FIG. 5. In response to the product selection operation from the user, the pharmaceutical package is selected from the pharmaceutical package name or the pharmaceutical package is selected from the symptoms, and the pharmaceutical package desired to be purchased is selected. When this process ends, the process proceeds to step S113.

[0127] In step S113, the control unit 30 performs a product determination process of determining the pharmaceutical package provided from the product offering device 100. This product determination process corresponds to the product determination process (step S24) shown in FIG. 5. When there is a product determination operation from the user, the pharmaceutical package provided from the product offering device 100 is determined. When this process ends, the process proceeds to step S114.

[0128] In step S114, the control unit 30 performs a user-specific information transmission process to acquire the medication history information associated with the user's specific information. This user-specific information transmission process corresponds to the user-specific information transmission process (step S25) shown in FIG. 5, and transmits history information request information to the server 200 in association with the user's specific information. When this process ends, the process proceeds to step S115.

[0129] In step S115, the control unit 30 determines whether or not it has received medication history information associated with the user's specific information from the server 200. If the control unit 30 determines that it has received medication history information associated with the user's specific information, the process proceeds to step S116. If it determines that it has not received the medication history information associated with the user's specific information, it waits until it receives the medication history information associated with the user's specific information.

[0130] In step S116, the control unit 30 performs a medication history information acquisition process for acquiring medication history information. This medication history information acquisition process corresponds to the medication history information acquisition process (step S27) shown in FIG. 5, and stores the medication history information associated with the user's specific information received from the server 200 in the control storage unit 41. When this process ends, the process proceeds to step S117.

[0131] In step S117, the control unit 30 performs a health damage suppression process. This medication history information acquisition process corresponds to the health damage suppression process (step S28) shown in FIG. 5, and will be described in detail later with reference to FIG. 7. When this process ends, the process proceeds to step S118.

[0132] In step S118, the control unit 30 determines whether or not to permit the provision of the pharmaceutical package determined in the above product determination process and desired to be purchased. If the control unit 30 determines that the provision of the pharmaceutical package desired to be purchased is permitted, the process proceeds to step S119. If it determines that the provision of the pharmaceutical package desired to be purchased is not permitted, the process proceeds to step S120.

[0133] In step S119, the control unit 30 performs a provided product determination process to determine the pharmaceutical package to be provided. This provided product determination process corresponds to the provided product determination process (step S30) shown in FIG. 5, and determines the pharmaceutical package desired to be purchased and the provided quantity. When this process ends, the process proceeds to step S121.

[0134] In step S120, the control unit 30 performs a purchase non - permission display process to cause the display unit 10 to display a purchase non - permission image. In this purchase non - permission display process, based on the reason (non - permission data described later) for not permitting the provision of the pharmaceutical package by the above - mentioned health hazard suppression process, a purchase non - permission image indicating that it cannot be sold because there is a risk of health hazards is displayed on the display unit 10. Then, the information of the pharmaceutical package desired to be purchased, the provided quantity, and the user's unique information, etc. are discarded (erased). When this process ends, the process returns to step S102.

[0135] In step S121, the control unit 30 performs a purchase price payment confirmation process. This purchase price payment confirmation process corresponds to the purchase price payment confirmation processes (step S12, step S31) shown in FIGS. 4 and 5. Based on the determined pharmaceutical package and the provided quantity, the purchase price is calculated, and the payment from the user is confirmed from the money information input / output unit 60. If the payment from the user is sufficient for the purchase price, the process proceeds to step S122 to provide the pharmaceutical package to the user. If the payment from the user is not sufficient for the purchase price, the system waits until the payment from the user is sufficient for the purchase price. Also, when the payment from the user exceeds the purchase price, the change is calculated and the calculated change is discharged from the change outlet 18.

[0136] In step S122, the control unit 30 performs a product provision process to provide the determined pharmaceutical package. This product provision process corresponds to the product provision processes (step S13, step S32) shown in FIGS. 4 and 5, and drives the drive device 50 to convey the determined number of pharmaceutical packages to the product outlet 12. When this process ends, the process proceeds to step S123.

[0137] In step S123, the control unit 30 performs a provision display process of causing the display unit 10 to display that the provision of the pharmaceutical package has been completed. In this provision display process, a provision completion image indicating that the provision of the pharmaceutical package has been completed is displayed on the display unit 10. Also, when combined use caution display data described later is set, a combined use caution image cautioning against the combined use of the components of the pharmaceutical package provided this time with the components of the pharmaceutical packages provided in the past is displayed on the display unit 10 together with the provision completion image. When this process ends, the process proceeds to step S124.

[0138] In step S124, when the control unit 30 provides the determined pharmaceutical package, it performs a purchase information transmission process. This purchase information transmission process corresponds to the purchase information transmission processes (step S14, step S33) shown in FIGS. 4 and 5, and transmits the information of the pharmaceutical package provided in association with the user's unique information to the server 200. Then, the information of the pharmaceutical package for which purchase is desired, the user's unique information, etc. are discarded (deleted). When this process ends, the process returns to step S102.

[0139] Although illustration is omitted, in addition to the main control process shown in FIG. 6 as the control process of the product provision processing device 100, it includes a reception interrupt process etc. performed by receiving various information from the server control unit 210.

[0140] (Health hazard suppression process) Next, the details of the health hazard suppression process performed by the product provision processing device 100 will be described. FIG. 7 is an example of a flowchart showing the health hazard suppression process of the product provision processing device according to Embodiment 1.

[0141] As shown in FIG. 7, in step S200, the control unit 30 performs a medication estimated component amount calculation process. In this medication estimated component amount calculation process, a medication estimated component amount is calculated. Details of this medication estimated component amount calculation process will be described later with reference to FIG. 8. When this process ends, the process proceeds to step S211.

[0142] In step S211, the control unit 30 performs a medication upper limit value extraction process. In this medication upper limit value extraction process, referring to the pharmaceutical package component information as shown in FIG. 3(a), the "medication upper limit value" of the abuse prevention component included in the pharmaceutical package for which purchase is desired is extracted. When this process ends, the process proceeds to step S212.

[0143] In step S212, the control unit 30 determines whether the medication estimated component amount exceeds the medication upper limit value for the abuse prevention component included in the pharmaceutical package desired to be purchased by the user. If the control unit 30 determines that the medication estimated component amount exceeds the medication upper limit value, the process proceeds to step S214. If the control unit 30 determines that the medication estimated component amount does not exceed the medication upper limit value (the medication estimated component amount is less than or equal to the medication upper limit value), the process proceeds to step S213.

[0144] In step S213, if the control unit 30 determines that the medication estimated component amount exceeds the medication upper limit value, it determines whether the number of the same pharmaceutical packages desired to be purchased is plural. If the control unit 30 determines that the number of the same pharmaceutical packages desired to be purchased is plural, the process proceeds to step S214. If the control unit 30 determines that the number of the same pharmaceutical packages desired to be purchased is not plural, in order not to permit the provision of the pharmaceutical package desired to be purchased, the process proceeds to step S222.

[0145] In step S214, the control unit 30 performs a calculation process for the available permitted number. In the calculation process of the available permitted quantity, subtract 1 from the number of pharmaceutical packages desired to be purchased, perform the same processing as in steps S200 to S212, and determine whether the estimated dosage component amount exceeds the upper limit of the dosage for the abuse prevention components included in the subtracted number of pharmaceutical packages. Then, when the estimated dosage component amount does not exceed the upper limit of the dosage, determine the subtracted number as the "permitted quantity". When the estimated dosage component amount exceeds the upper limit of the dosage, repeat the above processing until the subtracted number = 1. When the estimated dosage component amount no longer exceeds the upper limit of the dosage, determine the subtracted number at that time as the "permitted quantity". Even when the subtracted number = 1 (that is, the number of pharmaceutical packages to be provided this time is 1) and the estimated dosage component amount exceeds the upper limit of the dosage, determine the permitted quantity = 0. After this process ends, transfer the process to step S215.

[0146] In step S215, the control unit 30 determines whether there is an available permitted quantity. That is, the control unit 30 determines whether the permitted quantity > 0. When the control unit 30 determines that there is an available permitted quantity, it transfers the process to step S216. When it determines that there is no available permitted quantity, in order not to permit the provision of the pharmaceutical packages desired to be purchased, it transfers the process to step S222.

[0147] In step S216, the control unit 30 replaces the provided quantity with the permitted quantity. After this process ends, it transfers the process to step S217.

[0148] In step S217, the control unit 30 determines the provided quantity and sets the provision permission data that permits the provision of the pharmaceutical packages desired to be purchased. After this process ends, it transfers the process to step S218.

[0149] As a result, when the estimated dose component amount of the abuse prevention component included in the pharmaceutical package desired to be purchased by the user does not exceed the upper limit of the dose (the estimated dose component amount is less than or equal to the upper limit of the dose), the provision of the pharmaceutical package is permitted, so that health damage due to excessive intake of the medicine can be prevented.

[0150] In addition, when providing a plurality of the same pharmaceutical packages, it is possible to provide the pharmaceutical packages up to the permitted number that does not result in excessive intake of the medicine, and while preventing health damage, it is possible to provide the pharmaceutical packages that are minimally necessary for health recovery.

[0151] In the present embodiment, when there are a plurality of pharmaceutical packages desired to be purchased by the user and they are different pharmaceutical packages, from the viewpoint of suppressing health damage, it is difficult to determine which pharmaceutical package should be provided without going through a pharmacist, so the provision of both pharmaceutical packages is configured not to be permitted.

[0152] Note that in the present embodiment, when there are a plurality of pharmaceutical packages desired to be purchased and they are different pharmaceutical packages, it may be configured to permit only the provision of pharmaceutical packages in which the estimated dose component amount does not exceed the upper limit of the dose, or to permit only the provision of pharmaceutical packages with a small estimated dose component amount.

[0153] In step S218, the control unit 30 refers to the medication history information (FIG. 3(b)) associated with the concomitant use contraindication information and the user's unique information, and determines whether a pharmaceutical package containing a component that is a contraindicated combination has been provided in the past for the components included in the pharmaceutical package desired to be purchased. When the control unit 30 determines that a pharmaceutical package containing a component that is a contraindicated combination has been provided in the past, the process proceeds to step S221. When the control unit 30 determines that a pharmaceutical package containing a component that is a contraindicated combination has not been provided in the past, the process proceeds to step S219.

[0154] In step S219, the control unit 30 refers to the medication history information (Fig. 3(b)) associated with the combined use taboo information and the user's unique information, and determines whether a pharmaceutical package containing components that are a cautionary combination has been provided in the past for the components included in the pharmaceutical package for which purchase is desired. If the control unit 30 determines that a pharmaceutical package containing components that are a cautionary combination has been provided in the past, the process proceeds to step S220. If it determines that a pharmaceutical package containing components that are a cautionary combination has not been provided in the past, the current health hazard suppression process ends while retaining the provision permission data that permits the provision of the pharmaceutical package for which purchase is desired.

[0155] In step S220, the control unit 30 sets the combined use caution display data for causing the display unit 10 to display a message cautioning against the combined use of the components included in the pharmaceutical package for which purchase is desired with the components of the pharmaceutical packages provided in the past. When this process ends, the current health hazard suppression process ends while retaining the provision permission data that permits the provision of the pharmaceutical package for which purchase is desired.

[0156] As a result, if the components included in the pharmaceutical package desired to be purchased by the user are a cause for concern when combined with the components of the pharmaceutical packages provided to that user in the past, although the pharmaceutical package will be provided, a message cautioning against the combined use will be displayed, thereby alerting the user and preventing the occurrence of health hazards.

[0157] In step S221, the control unit 30 sets the combined use prohibition display data for causing the display unit 10 to display a message indicating that the combined use of the pharmaceutical package for which purchase is desired with the components of the pharmaceutical packages provided in the past is prohibited. When this process ends, the process proceeds to step S222.

[0158] In step S222, the control unit 30 sets non - permission data for not permitting the provision of the pharmaceutical package desired to be purchased. Also, even if the provision of the pharmaceutical package desired to be purchased in step S213 or step S217 is permitted so as not to cause over - ingestion of the medicine, from the viewpoint of the contraindicated combination of medicines, the permission data is replaced with non - permission data, and the provision of the pharmaceutical package desired to be purchased is not permitted. When this process ends, the current health - damage suppression process ends.

[0159] Thereby, when the estimated dose component amount of the abuse - prevention component contained in the pharmaceutical package desired to be purchased by the user exceeds the upper limit value of the dose, the provision of the pharmaceutical package is not permitted, so that health damage due to over - ingestion of the medicine can be prevented. In particular, since the component amount of the abuse - prevention component contained in the pharmaceutical package is being judged, for users taking the same abuse - prevention component, without being limited to the same pharmaceutical package or being distinguished between pioneer medicines and follow - on medicines (generic medicines), health damage due to over - ingestion of the medicine can be more firmly prevented.

[0160] Also, when the components contained in the pharmaceutical package desired to be purchased by the user are prohibited from being used in combination with the components of the pharmaceutical package provided to that user in the past, a message indicating that the combination is prohibited is displayed, and the provision of the pharmaceutical package is not permitted, so that health damage caused by the combination (contraindicated combination) of medicines can be prevented.

[0161] Furthermore, since the permission for the provision of the pharmaceutical package is judged from two viewpoints: the viewpoint of over - ingestion of the medicine and the viewpoint of the combination (contraindicated combination) of medicines, health damage caused by medicines can be comprehensively prevented.

[0162] In the health damage suppression process of this embodiment, the permission to provide a pharmaceutical package may also be determined from the perspective of the age at which taking medicine is not allowed. When configured in this way, refer to the pharmaceutical package component information (Fig. 3(a)), extract the "age at which taking medicine is not allowed" of the pharmaceutical package for which purchase is desired, and when the user's age corresponds to the "age at which taking medicine is not allowed", the provision of the pharmaceutical package for which purchase is desired may be configured not to be permitted.

[0163] Also, in the health damage suppression process of this embodiment, the permission to provide a pharmaceutical package is determined from two perspectives: the perspective of excessive intake of pharmaceuticals and the perspective of combinations (contraindications to combined use) of pharmaceuticals. However, it may be configured to determine the permission to provide a pharmaceutical package from only one of the perspectives of excessive intake of pharmaceuticals or combinations (contraindications to combined use) of pharmaceuticals.

[0164] (Estimated drug component amount calculation process) Next, the details of the estimated drug component amount calculation process performed by the product providing processing device 100 will be described. Fig. 8 is an example of a flowchart showing the estimated drug component amount calculation process of the product providing processing device according to Embodiment 1. Specifically, Fig. 8(a) is an example of a flowchart showing the estimated drug component amount calculation process of the product providing processing device according to Embodiment 1, and Fig. 8(b) is an example of a flowchart showing the estimated drug component amount calculation process of the product providing processing device according to a modified example of Embodiment 1.

[0165] Note that the calculation contents of the estimated drug component amount calculation process shown in Fig. 8(a) will also be described in an example of the estimated drug component amount shown in Fig. 9(a) below. Similarly, the calculation contents of the estimated drug component amount calculation process of the modified example shown in Fig. 8(b) will also be described in an example of the estimated drug component amount shown in Fig. 9(b) below.

[0166] As shown in Fig. 8(a), in step S201, the control unit 30 performs an abuse prevention component extraction process. In this abuse prevention component extraction process, referring to the pharmaceutical package component information (Figure 3(a)), from the information of the pharmaceutical packages desired to be purchased, the "abuse prevention components" that may cause health hazards for each pharmaceutical package desired to be purchased are extracted. Here, when different pharmaceutical packages are desired to be purchased simultaneously, the abuse prevention components are extracted for each pharmaceutical package. When this process is completed, the process proceeds to step S202.

[0167] In step S202, the control unit 30 performs a provided pharmaceutical package acquisition process. In this provided pharmaceutical package acquisition process, referring to the medication history information associated with the user's unique information (see Figure 3(b)), pharmaceutical packages containing the same abuse prevention components as the abuse prevention components extracted in step S201 are extracted, and the extracted pharmaceutical packages are determined as "provided pharmaceutical packages". Note that if there are no pharmaceutical packages containing the same abuse prevention components as the abuse prevention components extracted in step S201, no provided pharmaceutical packages will be determined. When this process is completed, the process proceeds to step S203.

[0168] In step S203, the control unit 30 performs a specific component amount acquisition process. In this specific component amount acquisition process, referring to the pharmaceutical package component information (Figure 3(a)), the "content per package (specific component amount)" of the abuse prevention components for the pharmaceutical packages desired to be purchased and the provided pharmaceutical packages is acquired. When this process is completed, the process proceeds to step S204.

[0169] In step S204, the control unit 30 performs a cumulative provided quantity calculation process. In this cumulative supply quantity calculation process, the medication history information (Figure 3(b)) associated with the user's unique information is referred to, the "quantity already supplied (the quantity of the pharmaceutical packages already supplied in the past)" of the pharmaceutical packages desired to be purchased and the already supplied pharmaceutical packages is extracted, and the "cumulative supply quantity" is calculated by summing up the quantity already supplied and the supply quantity (the supply quantity this time) for each pharmaceutical package. That is, the cumulative supply quantity is calculated by the following formula. Cumulative supply quantity = Quantity already supplied + Supply quantity When this process ends, the process proceeds to step S205.

[0170] In step S205, the control unit 30 performs a supply package specific component quantity calculation process. In this supply package specific component quantity calculation process, the specific component quantity acquired in step S203 above and the cumulative supply quantity are multiplied for each pharmaceutical package to calculate the "supply package specific component quantity". That is, the supply package specific component quantity is calculated by the following formula. Supply package specific component quantity = Specific component quantity × Cumulative supply quantity When this process ends, the process proceeds to step S206.

[0171] In step S206, the control unit 30 performs a cumulative specific component quantity calculation process. In this cumulative specific component quantity calculation process, the supply package specific component quantities calculated for each pharmaceutical package are summed up for each abuse prevention component to calculate the "cumulative specific component quantity". When this process ends, the process proceeds to step S207.

[0172] In step S207, the control unit 30 refers to the medication history information (see Figure 3(b)) associated with the user's unique information, extracts the "daily dosage" and "number of days elapsed" of the abuse prevention components included in the pharmaceutical packages desired to be purchased and the already supplied pharmaceutical packages, multiplies the daily dosage and the number of days elapsed extracted for each pharmaceutical package, and calculates the "quantity of components already taken". That is, the quantity of components already taken is calculated by the following formula. Quantity of components already taken = Daily dosage × Number of days elapsed When this process ends, the process proceeds to step S208.

[0173] In step S208, the control unit 30 sums up the administered component amounts calculated for each pharmaceutical package for each abuse-preventing component to calculate the "total administered component amount". When this process ends, the process proceeds to step S209.

[0174] In step S209, the control unit 30 performs a dosage estimation component amount determination process. In this dosage estimation component amount determination process, the "dosage estimation component amount" is calculated by subtracting the total administered component amount from the total specific component amount. That is, the dosage estimation component amount is calculated by the following formula. Dosage estimation component amount = Total specific component amount - Total administered component amount When this process ends, the process proceeds to step S211 (see FIG. 7).

[0175] FIG. 8(b) shows a dosage estimation component amount calculation process of the product providing apparatus according to a modification of Embodiment 1. The same process (abuse-preventing component extraction process) as the dosage estimation component amount calculation process shown in FIG. 8(a) is denoted by the same reference numerals, and the description of the process content is omitted.

[0176] As shown in FIG. 8(b), in step S231, the control unit 30 performs a current provision quantity acquisition process. In this current provision quantity acquisition process, the provision quantity for each pharmaceutical package desired to be purchased by the user is acquired. When this process ends, the process proceeds to step S232.

[0177] In step S232, the control unit 30 performs a specific component amount calculation process for the desired purchase. In this specific component amount calculation process for the desired purchase, the specific component amount acquired in step S203 above and the current provision quantity are multiplied for each pharmaceutical package desired to be purchased to calculate the "total specific component amount for the day". That is, the total specific component amount for the day is calculated by the following formula. Specific component amount for the desired purchase package = Specific component amount × Current provision quantity When this process ends, the process proceeds to step S233.

[0178] In step S233, the control unit 30 performs a calculation process for the cumulative specific ingredient amount of the desired purchases. In this calculation process for the cumulative specific ingredient amount of the desired purchases, the specific ingredient amounts of the desired purchase packages calculated for each pharmaceutical package are totaled for each abuse prevention ingredient to calculate the "cumulative specific ingredient amount of the desired purchase packages". When this process ends, the process proceeds to step S234.

[0179] In step S234, the control unit 30 performs a process for obtaining the total remaining estimated ingredient amount. In this process for obtaining the total remaining estimated ingredient amount, the medication history information (Fig. 3(b)) associated with the user's unique information is referred to, and the "total remaining estimated ingredient amount" for the abuse prevention ingredient extracted in step S201 is obtained. This total remaining estimated ingredient amount is the information stored in the medication history information as described in Fig. 3(b). When this process ends, the process proceeds to step S235.

[0180] In step S235, the control unit 30 performs a process for determining the estimated medication ingredient amount. In this process for determining the estimated medication ingredient amount, the total remaining estimated ingredient amount is added to the cumulative specific ingredient amount of the desired purchase packages to calculate the "estimated medication ingredient amount". That is, the estimated medication ingredient amount is calculated by the following formula. Estimated medication ingredient amount = Cumulative specific ingredient amount of the desired purchase packages + Total remaining estimated ingredient amount When this process ends, the process proceeds to step S211 (see Fig. 7).

[0181] In the process for calculating the estimated medication ingredient amount shown in Fig. 8(a) and the process for calculating the estimated medication ingredient amount shown in Fig. 8(b), although the intermediate formulas for calculating the estimated medication ingredient amount are different, ultimately the same estimated medication ingredient amount is calculated.

[0182] (Example of the estimated medication ingredient amount) Next, an example of the estimated drug component amount calculated in the estimated drug component amount calculation process (see FIG. 8) will be described with reference to FIG. 9. FIG. 9 shows an example of the estimated drug component amount of the product providing processing apparatus according to Embodiment 1. Specifically, FIG. 9(a) shows an example of the estimated drug component amount calculated by the estimated drug component amount calculation process shown in FIG. 8(a), and FIG. 9(b) shows an example of the estimated drug component amount calculated by the estimated drug component amount calculation process shown in FIG. 8(b).

[0183] In FIG. 9, it is assumed that the user purchased 2 packages of the pharmaceutical product "Headache Medicine ABC" on "2024 / 01 / 01" in the past and purchased 1 package of the pharmaceutical product "Headache Medicine Gold" on "2024 / 01 / 08" in the past, and the current date is "2024 / 01 / 09". Then, an example of the estimated drug component amount calculated when the user tries to newly purchase 1 package of the pharmaceutical product "Headache Medicine ABC" from the product providing processing apparatus 100 will be described.

[0184] According to the above-described past purchase information of the user, as shown in FIG. 3(b), as the drug history information, the abuse prevention component "Component A" for the user's unique information and various "pharmaceutical package information" for Component A are stored in association with each other. As the "pharmaceutical package information", for the pharmaceutical package of "Headache Medicine ABC", the content per package (specific component amount) of "2000 mg", the number of provided packages of "2", the first provided date of "2024 / 01 / 01", the daily drug intake of "400 mg", the number of elapsed days of "8", and the remaining estimated component amount of "800 mg" are stored in association with each other. Furthermore, for the pharmaceutical package of "Headache Medicine Gold", the content per package (specific component amount) of "1000 mg", the number of provided packages of "1", the first provided date of "2024 / 01 / 08", the daily drug intake of "500 mg", the number of elapsed days of "1", and the remaining estimated component amount of "500 mg" are stored in association with each other. Then, for the user's unique information, the "total remaining estimated component amount" of component A, which is the sum of the remaining estimated component amount for the pharmaceutical package of "Headache Medicine ABC" and the remaining estimated component amount for the pharmaceutical package of "Headache Medicine Gold", is "1300 mg", and this is stored in association with it.

[0185] As shown in Fig. 9(a), in the estimated component amount calculation process for taking medicine shown in Fig. 8(a), first, "component A" is extracted as an abuse prevention component from the pharmaceutical package of "Headache Medicine ABC" that the user wishes to purchase, and the pharmaceutical packages of "Headache Medicine ABC" and "Headache Medicine Gold" are extracted as the provided pharmaceutical packages containing the same component A from the medicine-taking history information associated with the user's unique information.

[0186] Next, referring to the medicine-taking history information associated with the user's unique information, the provided quantity and the current provided quantity are added for each pharmaceutical package to calculate the "cumulative provided quantity". Therefore, the "cumulative provided quantity" for the pharmaceutical package of "Headache Medicine ABC" is "3", and the "cumulative provided quantity" for the pharmaceutical package of "Headache Medicine Gold" is "1".

[0187] After calculating the cumulative provided quantity for each pharmaceutical package, the specific component amount and the cumulative provided quantity are multiplied for each pharmaceutical package to calculate the "specific component amount of the provided package". Therefore, the "specific component amount of the provided package" for the pharmaceutical package of "Headache Medicine ABC" is "6000 mg", and the "specific component amount of the provided package" for the pharmaceutical package of "Headache Medicine Gold" is "1000 mg".

[0188] After calculating the specific component amount of the provided package for each pharmaceutical package, the specific component amounts of the provided packages calculated for each pharmaceutical package are totaled for each abuse prevention component to calculate the "cumulative specific component amount". Therefore, the "cumulative specific component amount" of the abuse prevention component "component A" is "7000 mg".

[0189] Next, for each pharmaceutical package, multiply the daily dose and the number of elapsed days to calculate the "amount of component taken". Therefore, the "amount of component taken" for the pharmaceutical package of "Headache Medicine ABC" is "3200 mg", and the "amount of component taken" for the pharmaceutical package of "Headache Medicine Gold" is "500 mg".

[0190] After calculating the amount of component taken for each pharmaceutical package, sum up the amounts of component taken calculated for each pharmaceutical package for each abuse-preventing component to calculate the "cumulative amount of component taken". Therefore, the "cumulative amount of component taken" of "Component A" of the abuse-preventing component is "3700 mg".

[0191] Then, subtract the cumulative amount of component taken from the cumulative specific component amount to calculate the "estimated amount of component taken". Therefore, the "estimated amount of component taken" of "Component A" of the abuse-preventing component is "3300 mg".

[0192] If the provision determination value obtained by subtracting the upper limit of the amount taken from the estimated amount of component taken is negative (provision determination value < 0), it means that the estimated amount of component taken is less than or equal to the upper limit of the amount taken, and the provision of the pharmaceutical package for which purchase is desired will be permitted.

[0193] Next, an example of the estimated amount of component taken calculated by the estimated amount of component taken calculation process shown in FIG. 8(b) will be described.

[0194] As shown in FIG. 9(b), in the estimated amount of component taken calculation process shown in FIG. 8(b), first, extract "Component A" as an abuse-preventing component from the pharmaceutical package of "Headache Medicine ABC" for which purchase is desired, and extract the pharmaceutical packages of "Headache Medicine ABC" and "Headache Medicine Gold" as the provided pharmaceutical packages containing the same Component A from the medication history information associated with the user's unique information.

[0195] Next, refer to the medication history information associated with the user's unique information to obtain the number of provided pharmaceutical packages for which purchase is desired. Therefore, the "quantity provided this time" for the pharmaceutical package of "Headache Medicine ABC" that is desired to be purchased is "1 piece".

[0196] When calculating the quantity provided for the desired pharmaceutical package, multiply the specific component quantity and the quantity provided this time for each desired pharmaceutical package to calculate the "specific component quantity of the desired package". Therefore, the "specific component quantity of the desired package" for the pharmaceutical package of "Headache Medicine ABC" is "2000 mg".

[0197] When calculating the specific component quantity of the desired package for each desired pharmaceutical package, sum up the specific component quantities of the desired packages calculated for each desired pharmaceutical package for each abuse prevention component to calculate the "cumulative specific component quantity of the desired package". Here, since there are no other desired pharmaceutical packages except for "Headache Medicine ABC", the "cumulative specific component quantity of the desired package" of "Component A" of the abuse prevention component is "2000 mg".

[0198] Refer to the medication history information associated with the user's unique information to obtain the "total remaining estimated component quantity" for "Component A" of the abuse prevention component.

[0199] Then, add the total remaining estimated component quantity to the cumulative specific component quantity of the desired package to calculate the "estimated medication component quantity". Therefore, the "estimated medication component quantity" of "Component A" of the abuse prevention component is "3300 mg".

[0200] If the provision determination value obtained by subtracting the medication upper limit value from the estimated medication component quantity is negative (provision determination value < 0), it means that the estimated medication component quantity is below the medication upper limit value, and the provision of the desired pharmaceutical package will be permitted.

[0201] In this way, based on the information about the pharmaceutical package desired to be purchased by the user and the medication history information associated with the user's unique information, it is possible to calculate the estimated medication component amount for estimating the component amount of the abuse prevention component within a predetermined period. When the estimated medication component amount exceeds the upper limit of the medication amount within one time or the continuous medication period estimated from the estimated risk amount for each abuse prevention component, the provision of the pharmaceutical package desired to be purchased is not permitted, so that it is possible to prevent health damage caused by excessive intake of pharmaceuticals.

[0202] Note that the calculation formula for the estimated medication component amount can be freely designed with appropriate changes by associating elements for preventing health damage.

[0203] (Server Health Damage Suppression Process) Next, the details of the server health damage suppression process performed by the server 200 will be described. FIG. 10 is an example of a flowchart showing the server health damage suppression process of the server according to Embodiment 1.

[0204] This server health damage suppression process is a process corresponding to the server health damage suppression process (step S4) shown in FIG. 4 and is a process performed when receiving information on a pharmaceutical package reserved for purchase from the user terminal device 300. The server health damage suppression process in the server 200 shown in FIG. 10 performs the same process as the health damage suppression process in the product providing processing device 100 shown in FIG. 7, although the control targets are different between the server control unit 210 and the control unit 30. Those that perform the same process by replacing the control target from the control unit 30 to the server control unit 210 are given the same reference numerals as the health damage suppression process in the product providing processing device 100 shown in FIG. 7, and the description of the processing content thereof is omitted.

[0205] As shown in FIG. 10, in step S200, the server control unit 210 performs an estimated medication component amount calculation process. This estimated medication component amount calculation process performs the same process as the estimated medication component amount calculation process shown in FIG. 8 by replacing the control target from the control unit 30 to the server control unit 210.

[0206] In step S301, when the server control unit 210 determines that a pharmaceutical package containing components that are a caution combination has been provided in the past, in order to cause the user terminal device 300 to display that the components included in the reserved pharmaceutical package should be cautioned about when used in combination with the components of the pharmaceutical package provided in the past, the server control unit 210 transmits combination caution display data to the user terminal device �00.

[0207] In step S302, when the server control unit 210 determines that a pharmaceutical package containing components that are a contraindication combination has been provided in the past, in order to cause the user terminal device 300 to display that the combined use of the reserved pharmaceutical package with the components of the pharmaceutical package provided in the past is prohibited, the server control unit 210 transmits combination prohibition display data to the user terminal device 300.

[0208] In step S303, when the estimated dosage component amount of the abuse prevention component included in the reserved pharmaceutical package does not exceed the dosage upper limit value and a pharmaceutical package containing components that are a contraindication combination has not been provided in the past, the server control unit 210 performs permission information transmission processing. In this permission information transmission processing, permission information for permitting the provision of the reserved pharmaceutical package, pharmaceutical information of the reserved pharmaceutical package, the number of the reserved pharmaceutical packages as the number of provided packages, and code information for issuing a QR code are transmitted to the user terminal device 300. When this processing is completed, the processing proceeds to step S218.

[0209] In step S304, when the estimated dosage component amount of the abuse prevention component included in the reserved pharmaceutical package exceeds the dosage upper limit value or a pharmaceutical package containing components that are a contraindication combination has been provided in the past, the server control unit 210 performs non - permission information transmission processing. In this non - permission information transmission processing, non - permission information for not permitting the provision of the reserved pharmaceutical package and pharmaceutical information of the reserved pharmaceutical package are transmitted to the user terminal device 300. When this processing is completed, the current server health hazard suppression processing is terminated.

[0210] In addition, in the server health damage suppression process of this embodiment, the permission to provide the pharmaceutical package is determined from two perspectives: the perspective of overdose of pharmaceuticals and the perspective of combination (contraindication of combined use) of pharmaceuticals. However, the permission to provide the pharmaceutical package may be determined from only one of the perspectives of overdose of pharmaceuticals or combination (contraindication of combined use) of pharmaceuticals.

[0211] [Display Screen of Commodity Provision Processing Device] With reference to FIGS. 11 to 13, an example of the display screen displayed on the display unit 10 of the commodity provision processing device 100 will be described.

[0212] (Display Screen When Receiving a Pharmaceutical Package Reserved for Purchase from a User Terminal Device) First, with reference to FIG. 11, the display screen displayed on the display unit 10 when receiving the reserved pharmaceutical package from the commodity provision processing device 100 will be described. FIG. 11 is an example of the display screen when receiving the reserved pharmaceutical package in the commodity provision processing device according to Embodiment 1.

[0213] FIG. 11(a) is an example of the reception display screen when performing reception standby processing for receiving an operation from the user.

[0214] As shown in FIG. 11(a), on the reception display screen, a purchase operation image (for example, a character image of "Purchase Goods") for receiving the purchase operation of the pharmaceutical package from the user and a reception operation image (for example, a character image of "Receive Reserved Purchase Goods") for receiving the reception operation of the reserved pharmaceutical package from the user are displayed. The user performs the purchase operation of the pharmaceutical package by touching the purchase operation image, and performs the reception operation of the reserved pharmaceutical package by touching the reception operation image.

[0215] FIG. 11(b) is an example of the QR code request display screen for requesting QR code information when there is a reception operation of the reserved pharmaceutical package from the user.

[0216] As shown in FIG. 11(b), on the QR code request display screen, a display for requesting QR code information including the information of the pharmaceutical package reserved for purchase is performed. The user causes the user terminal device 300 to display the QR code information including the information of the pharmaceutical package reserved for purchase, and causes the code reader 16 of the product providing processing device 100 to read the displayed QR code information.

[0217] FIG. 11(c) is an example of a purchase reservation confirmation display screen when the product providing processing device 100 reads the QR code information and confirms the pharmaceutical package reserved for purchase.

[0218] As shown in FIG. 11(c), on the purchase reservation confirmation display screen, the information of the pharmaceutical package reserved for purchase is displayed, and an image of a "Yes" button for determining the pharmaceutical package reserved for purchase and an image of a "No" button for canceling the pharmaceutical package reserved for purchase are displayed. When the user touches the image of the "Yes" button, the pharmaceutical package to be provided is determined, and the product providing processing device 100 performs a purchase payment confirmation process.

[0219] FIG. 11(d) is an example of a normal provision completion display screen when the payment for the purchase of the pharmaceutical package is completed and the provision of the pharmaceutical package is completed.

[0220] As shown in FIG. 11(d), on the normal provision completion display screen, a provision completion image (for example, a character image of "Please receive the product from the product outlet") notifying the user that the pharmaceutical product has been provided is displayed.

[0221] (Display screen when determining and purchasing a pharmaceutical package from the product providing processing device) Referring to FIG. 12, the display screen displayed on the display unit 10 when determining and purchasing a pharmaceutical package from the product providing processing device 100 will be described. FIG. 12 is an example of a display screen when determining and purchasing a pharmaceutical package in the product providing processing device according to Embodiment 1.

[0222] FIG. 12(a) is an example of a reception display screen when reception standby processing for receiving an operation from a user is being performed, and since it is the same as the reception display screen in FIG. 11(a), the description thereof will be omitted.

[0223] FIG. 12(b) is an example of a unique information request display screen that requests the user's unique information when there is a purchase operation of a pharmaceutical package from the user.

[0224] As shown in FIG. 12(b), on the unique information request display screen, a display for requesting the user's unique information is performed. Specifically, a my number input image for inputting the user's unique information by reading a my number card, a QR input image for inputting the user's unique information by reading a QR code of an app ID corresponding to the product providing system 1, and a camera input image for inputting the user's unique information from a face authentication or driver's license photographed by the external camera 20 are displayed. When the user touches the my number input image, the QR input image, or the camera input image, the product providing processing device 100 acquires the user's unique information according to the input method.

[0225] In the present embodiment, on the unique information request display screen, the user's unique information can be selectively selected from a plurality of input methods. However, the user's unique information may be acquired from only any one of the input methods, such as reading a my number card, reading a QR code of an app ID corresponding to the product providing system 1, inputting the user's unique information from face authentication by the external camera 20, or inputting the user's unique information from a driver's license. Further, the unique information request display screen may be configured to be displayed not after there is a purchase operation of a pharmaceutical package, but after determining the pharmaceutical package desired to be purchased (after the display of the pharmaceutical product determination screen in FIG. 12(d) described later).

[0226] FIG. 12(c) is an example of a purchase route selection screen for selecting a pharmaceutical package desired to be purchased after acquiring the user's unique information.

[0227] As shown in FIG. 12(c), on the purchase route selection screen, at least a product selection purchase route image for the user to directly select a pharmaceutical package and determine the pharmaceutical package to be purchased, and a symptom selection purchase route image for the user to select symptoms and determine the pharmaceutical package to be purchased are displayed. The user determines the purchase route by touching the product selection purchase route image or the symptom selection purchase route image, narrows down the pharmaceutical package based on various selection information, and determines the pharmaceutical package to be purchased.

[0228] FIG. 12(d) is an example of a pharmaceutical product determination screen when the user determines the pharmaceutical package to be purchased.

[0229] As shown in FIG. 12(d), on the pharmaceutical product determination screen, information on the pharmaceutical package to be purchased, an image of a "Yes" button for determining the pharmaceutical package to be purchased, and an image of a "No" button for canceling the pharmaceutical package to be purchased are displayed.

[0230] (Display screen after permission determination for providing a pharmaceutical package by health hazard suppression processing) When the user determines the pharmaceutical package to be purchased, the product providing processing device 100 performs a health hazard suppression process (see FIG. 7) and determines whether to permit the provision of the pharmaceutical package. FIG. 13 is an example of a display screen after permission determination for providing a pharmaceutical package by health hazard suppression processing in the product providing processing device according to Embodiment 1.

[0231] FIG. 13(a) is an example of a normal provision completion display screen when it is determined that the pharmaceutical package desired to be purchased by the user has no problems from either the perspective of excessive intake of pharmaceuticals or the perspective of combinations (concomitant use taboos) of pharmaceuticals in the health hazard suppression process, and the pharmaceutical package is provided.

[0232] As shown in FIG. 13(a), on the normal provision completion display screen, a provision completion image (for example, a character image of "Please receive the pharmaceutical package from the product outlet") notifying the user that the pharmaceutical package has been provided is displayed.

[0233] FIG. 13(b) is an example of a caution provision completion display screen when it is determined that, from the perspective of suppressing excessive intake of pharmaceuticals, the pharmaceutical package desired to be purchased by the user has no problem due to the health hazard suppression process, but there is a caution regarding the combined use of the components included in the desired pharmaceutical package with the components of the previously provided pharmaceutical packages.

[0234] As shown in FIG. 13(b), on the caution provision completion display screen, in addition to the provision completion image, a combined use caution image (for example, a character image of "Please be cautious about the combined use of Component A of the pharmaceutical ABC provided this time and Component B of the pharmaceutical Z") notifying that the pharmaceutical package to be provided this time should be cautious about the combined use with the components of the previously provided pharmaceutical packages is displayed.

[0235] FIG. 13(c) is an example of an excessive intake prevention display screen when it is determined that, from the perspective of suppressing excessive intake of pharmaceuticals, the pharmaceutical package desired to be purchased by the user has a problem due to the health hazard suppression process and the pharmaceutical package is not provided.

[0236] As shown in FIG. 13(c), on the excessive intake prevention display screen, together with a provision prohibition image (for example, a character image of "This pharmaceutical cannot be provided") notifying that the pharmaceutical package cannot be provided, an abuse prevention notification image (for example, a character image of "For the prevention of abuse of specific components") notifying the excessive intake of the abuse prevention component, which is the reason for prohibiting the provision of the pharmaceutical package, is displayed. Also, on the excessive intake prevention display screen, a pharmacist response image (for example, the text of "Please consult a pharmacist at a pharmacy or the like before purchasing") is displayed from the perspective of suppressing health hazards.

[0237] Figure 13(d) is an example of a combined use taboo display screen when it is determined that the pharmaceutical package desired to be purchased by the user is prohibited from being used in combination with the components included in the pharmaceutical package provided in the past due to the health damage suppression process, and the pharmaceutical package is not provided.

[0238] As shown in Figure 13(d), on the combined use taboo display screen, together with the prohibited provision image, a combined use taboo notification image (for example, the text "The component A of pharmaceutical ABC and the component C of pharmaceutical X fall under the combined use taboo") that notifies the combined use taboo, which is the reason for prohibiting the provision of the pharmaceutical package, is displayed. Also, on the combined use taboo display screen, an image for pharmacist response is displayed.

[0239] As described above, in the present embodiment, for the abuse prevention component included in the pharmaceutical package desired to be purchased by the user, when the estimated dose component amount exceeds the upper limit value of the dose, the provision of the pharmaceutical package is not permitted, so that health damage caused by excessive intake of the pharmaceutical can be prevented. In particular, since the amount of the component with respect to the abuse prevention component included in the pharmaceutical package is determined, the same abuse prevention component can be more firmly prevented from causing health damage to users who take the same abuse prevention component without being limited to the same pharmaceutical package or being distinguished between the first-developed pharmaceutical and the second-developed pharmaceutical (generic pharmaceutical).

[0240] Also, in the present embodiment, when providing a plurality of the same pharmaceutical packages, it is possible to provide the pharmaceutical packages up to the permitted number that does not result in excessive intake of the pharmaceutical, and while preventing health damage, provide the pharmaceutical packages that are minimally necessary for health recovery.

[0241] In this embodiment, the medication history information is managed by the server 200, and is configured to be transmitted from the server 200 to each product providing processing device 100. Therefore, the medication history information is shared by all the product providing processing devices 100. Even when purchasing a pharmaceutical package from the product providing processing devices 100 installed in different locations, when the estimated medication component amount obtained by summing up the abuse prevention components included in the pharmaceutical packages provided by the respective product providing processing devices 100 exceeds the medication upper limit value, the provision of the pharmaceutical package can be stopped. As a result, it is possible to prevent attempts to purchase a large amount of pharmaceutical packages at different locations due to drug overdose addiction, and prevent health damage caused by drug overdose.

[0242] In this embodiment, when the components included in the pharmaceutical package desired to be purchased by the user are prohibited from being used in combination with the components of the pharmaceutical packages provided in the past, a message indicating that the combination is prohibited is displayed, and the provision of the pharmaceutical package is not permitted. Therefore, it is possible to prevent health damage caused by a combination of medications (contraindicated combination).

[0243] Furthermore, since the permission to provide the pharmaceutical package is determined from two perspectives, namely, the perspective of drug overdose and the perspective of combination of medications (contraindicated combination), it is possible to comprehensively prevent health damage caused by medications.

[0244] The product providing processing device 100 of Embodiment 1 is configured as a vending machine capable of providing a pharmaceutical package. However, the pharmaceutical package may be stored in a store of a retailer such as a pharmacy, a drugstore, or a convenience store, and health damage suppression processing may be performed in the product providing processing device. When the provision of the pharmaceutical package is permitted, a store clerk may be configured to provide the pharmaceutical package. That is, the product providing processing device may be replaced with a POS terminal (cash register, self-checkout, semi-self-checkout) installed in front of the cash register of the retailer, a function expansion terminal connected to the POS terminal, or a clerk terminal operated by a store clerk of the retailer.

[0245] [Embodiment 2] The merchandise provision processing apparatus 400 according to Embodiment 2 is a function expansion terminal connected to the POS terminal 500. FIG. 14 is an example of a perspective view of the merchandise provision processing apparatus according to Embodiment 2. This merchandise provision processing apparatus 400 is installed inside the stores of retailers such as pharmacies, drugstores, and convenience stores.

[0246] As shown in FIG. 14, on the front side of the merchandise provision processing apparatus 400 according to Embodiment 2, there are provided a touch screen 410 capable of displaying an image and receiving a selection operation of the user, an external camera 420 for photographing the user, a code reader 430 capable of reading a QR code, and an IC card reader 440 capable of reading a My Number card.

[0247] The user operates the merchandise provision processing apparatus 400 according to Embodiment 2, and the same processing as that of the merchandise provision processing apparatus 100 according to Embodiment 1 is performed to determine the pharmaceutical package that the user wishes to purchase.

[0248] Then, when the pharmaceutical package desired to be purchased is determined, the merchandise provision processing apparatus 400 according to Embodiment 2 acquires the medication history information associated with the user's unique information from the server 200, performs the same processing as the health hazard suppression processing (see FIG. 7), and determines whether to permit the provision of the pharmaceutical package.

[0249] When the merchandise provision processing apparatus 400 determines to permit the provision of the pharmaceutical package by the health hazard suppression processing, it transmits to the POS terminal 500 the pharmaceutical information of the pharmaceutical package desired to be purchased, the number of units of the pharmaceutical package desired to be purchased, and a provision permission signal permitting the provision of the pharmaceutical package. When the merchandise provision processing apparatus 400 determines not to permit the provision of the pharmaceutical package by the health hazard suppression processing, it transmits a provision non - permission signal of the pharmaceutical package to the POS terminal 500.

[0250] When the POS terminal 500 receives the drug information, the number of items to be provided, and the provision permission signal of the drug package from the commodity provision processing device 400, the payment process for the drug package desired to be purchased becomes possible, and the salesclerk can provide the drug package. On the other hand, when the POS terminal 500 receives a non - permission signal from the commodity provision processing device 400, the payment process for the drug package desired to be purchased cannot be performed, and the salesclerk cannot provide the drug package.

[0251] Thus, the commodity provision processing device 400 according to the second embodiment can also achieve the same operations and effects as the commodity provision system 1 and the commodity provision processing device 100 according to the first embodiment.

[0252] Note that the commodity provision processing device 400 according to the second embodiment is configured as a function - extended terminal connected to the POS terminal 500, but the same applies to a POS terminal or a clerk terminal operated by a clerk in a store.

[0253] The commodity provision processing device 100 of the first embodiment is configured as a vending machine capable of providing drug packages, and the commodity provision processing device 400 of the second embodiment is configured as a POS terminal, a function - extended terminal connected to the POS terminal, or a clerk terminal operated by a clerk in a store, but the commodity provision processing device may be replaced with a server.

[0254] [Embodiment 3] The commodity provision processing device according to the third embodiment is a server and supports online sales via the Internet.

[0255] When a user desires to purchase a drug package via the Internet using a user terminal device, the server performs a process similar to the server health - hazard suppression process (see FIG. 10) on the drug package desired to be purchased and determines whether to permit the provision of the drug package.

[0256] When the server determines to permit the provision of the pharmaceutical package through the server health hazard suppression process, it transmits the pharmaceutical information of the pharmaceutical package desired to be purchased at an EC site, a drugstore, a predetermined store, etc., the number of units of the pharmaceutical package desired to be purchased, and a provision permission signal for permitting the provision of the pharmaceutical package. When the server determines not to permit the provision of the pharmaceutical package through the server health hazard suppression process, it transmits information to the user terminal device indicating that the provision of the pharmaceutical package cannot be permitted.

[0257] When an EC site, a drugstore, a predetermined store, etc. receive the pharmaceutical information, the number of units, and the provision permission signal of the pharmaceutical package desired to be purchased from the server, they provide the pharmaceutical package desired to be purchased by mail.

[0258] Thus, also by the product provision processing apparatus according to Embodiment 3, the same operations and effects as those of the product provision system 1 and the product provision processing apparatus 100 according to Embodiment 1 can be achieved.

[0259] It will be apparent to those skilled in the art that in the above-described embodiments, including the modified examples, the techniques of each embodiment can be applied to each other.

[0260] The above description is intended as an illustration only and not a limitation. Thus, it will be apparent to those skilled in the art that changes can be made to the embodiments of the present invention without departing from the scope of the claims.

[0261] The terms used in this specification and the claims should be construed as non-limiting terms. For example, the term "including" should be construed as "not limited to what is described as including." The term "comprising" should be construed as "not limited to what is described as comprising." The term "having" should be construed as "not limited to what is described as having."

Explanation of Reference Numerals

[0262] 1 Commodity provision system 10 Display unit 11 Operation input unit 16 Code reader 20 External camera 30 Control unit 40 Device program storage unit 100 Commodity provision processing device (vending machine) 200 Server 210 Server control unit 220 Database storage unit 230 Server program storage unit 300 User terminal device 400 Commodity provision processing device (function expansion terminal)

Claims

1. user identification means for identifying a user; component amount calculation means for calculating a specific component amount of a specific component included in a pharmaceutical package selected for purchase by the user when it is selected to purchase a pharmaceutical package containing a plurality of pharmaceuticals; medication estimated component amount calculation means for calculating a medication estimated component amount for estimating a component amount of a specific component within a predetermined period based on the specific component amount calculated by the component amount calculation means and medication history information regarding a pharmaceutical package previously provided to the user identified by the user identification means; abuse prevention determination means for determining whether or not the medication estimated component amount calculated by the medication estimated component amount calculation means exceeds a predetermined medication upper limit value; provision determination means capable of permitting the provision of the pharmaceutical package selected for purchase by the user when it is determined by the abuse prevention determination means that the medication estimated component amount is equal to or less than the medication upper limit value, and suspending the provision of the pharmaceutical package selected for purchase by the user when it is determined by the abuse prevention determination means that the medication estimated component amount exceeds the medication upper limit value A product providing system characterized by the above.

2. The component amount calculation means when it is selected to purchase a plurality of identical pharmaceutical packages by the user, calculates, as the specific component amount, the total component amount of the specific component included in the plurality of pharmaceutical packages; The provision determination means when it is selected to purchase a plurality of identical pharmaceutical packages by the user and it is determined by the abuse prevention determination means that the medication estimated component amount exceeds the medication upper limit value, while permitting the provision of the pharmaceutical packages up to the permitted number for which the medication estimated component amount is equal to or less than the medication upper limit value among the plurality of identical pharmaceutical packages, suspends the provision of the pharmaceutical packages exceeding the permitted number among the plurality of identical pharmaceutical packages The product providing system according to claim 1, characterized by the above.

3. The component amount calculation means when it is selected to purchase different pharmaceutical packages by the user, extracts the component amount of the specific component included in each pharmaceutical package, and calculates the specific component amount by summing up the extracted component amounts The product providing system according to claim 1, characterized by the above.

4. A plurality of product providing processing devices for providing pharmaceutical packages It includes a plurality of product providing processing devices and a server connected to be able to transmit and receive information through a public line. The server has storage means for storing the medication history information, and when receiving predetermined request information from the product providing processing device, has medication history information transmitting means for transmitting the medication history information stored in the storage means to the product providing processing device. The product providing processing device when providing a pharmaceutical package, has purchase information transmitting means for associating the information of the provided pharmaceutical package with the information of the user who provided the pharmaceutical package and transmitting it to the server. The product providing system according to claim 1, characterized in that.

5. When providing a pharmaceutical package, it further includes medication component amount adjusting means for reducing the estimated medication component amount every number of days elapsed since the date of providing the pharmaceutical package. The product providing system according to claim 1, characterized in that.

6. The estimated medication component amount calculating means when it is selected by the user to purchase a pharmaceutical package, subtracts the amount of medication components already taken, which is the daily dosage of the specific component multiplied by the number of days elapsed since the first day of the provision date, from the total specific component amount obtained by adding the specific component amount on the current day calculated by the component amount calculating means and the past component amount of the specific component included in the pharmaceutical packages provided in the past, and calculates the estimated medication component amount. The product providing system according to claim 5, characterized in that.

7. specific component extracting means for extracting specific components included in the pharmaceutical package selected by the user to purchase; contraindication prevention determination means for determining whether a pharmaceutical package containing a contraindicated component that is contraindicated in combination with the specific component calculated by the specific component extracting means has been provided in the past; and when the contraindication prevention determination means determines that a pharmaceutical package containing a contraindicated component has been provided in the past, it includes caution notice means for notifying cautionary information. The product providing system according to claim 1, characterized in that.

8. user identification means for identifying the user; and when it is selected by the user to purchase a pharmaceutical package containing a plurality of pharmaceuticals, component amount calculating means for calculating the specific component amount of the specific components included in the pharmaceutical package selected to be purchased. A dosage estimation component amount calculation means for calculating a dosage estimation component amount that estimates the component amount of a specific component within a predetermined period based on the specific component amount calculated by the component amount calculation means and the medication history information regarding the pharmaceutical packages previously provided to the user identified by the user identification means; An abuse prevention determination means for determining whether the dosage estimation component amount calculated by the dosage estimation component amount calculation means exceeds a predetermined dosage upper limit value; When the abuse prevention determination means determines that the dosage estimation component amount is equal to or less than the dosage upper limit value, permission is given to provide the pharmaceutical package selected for purchase by the user, and when the abuse prevention determination means determines that the dosage estimation component amount exceeds the dosage upper limit value, a provision determination means capable of terminating the provision of the pharmaceutical package selected for purchase by the user is provided A product provision processing apparatus characterized by the above.

9. In a program to be executed by a computer, A user identification process for identifying a user; When it is selected to purchase a pharmaceutical package containing a plurality of pharmaceuticals by the user, a component amount calculation process for calculating the specific component amount of the specific component contained in the pharmaceutical package selected for purchase; A dosage estimation component amount calculation process for calculating a dosage estimation component amount that estimates the component amount of a specific component within a predetermined period based on the specific component amount calculated by the component amount calculation process and the medication history information regarding the pharmaceutical packages previously provided to the user identified by the user identification process; An abuse prevention determination process for determining whether the dosage estimation component amount calculated by the dosage estimation component amount calculation process exceeds a predetermined dosage upper limit value; When the abuse prevention determination process determines that the dosage estimation component amount is equal to or less than the dosage upper limit value, permission is given to provide the pharmaceutical package selected for purchase by the user, and when the abuse prevention determination process determines that the dosage estimation component amount exceeds the dosage upper limit value, a provision determination process capable of terminating the provision of the pharmaceutical package selected for purchase by the user is provided A program characterized by the above.

Images